LIPOTEK

Lipotek is a privately held Australian company (ABN 51 098 824 509) with laboratories and offices on the campus of the Australian National University... Lipotek is dedicated to developing versatile antigen delivery modules that facilitate dendritic cell (DC) targeting and activation in vivo. DCs are antigen presenting cells that act as key regulators of the immune system. Depending on the antigen environment encountered, they exert either immunogenic or tolerogenic effects. Lipotek's approach to vaccine design is therefore to ensure that antigens are delivered to DCs, with simultaneous activation of DCs using cytokines and/or Toll-like receptor (TLR) ligands.

Also known as: Lipotek Pty Ltd

Registration numbers: 51 098 824 509 (W)